Market Trends of America Cancer Immunotherapy Industry
Breast Cancer Segment is Expected to Exhibit a Significant Market Growth Over the Forecast Period
The segment includes cancer immunotherapies for treating breast cancer, which is one of the most common cancers among women and most likely to affect women over the age of 50.
The segment is anticipated to grow during the forecast period owing to the high burden of breast cancer and increasing demand for cancer immunotherapies. For instance, according to the American Cancer Society, the burden of breast cancer increased significantly in the United States, and the total number of cases ramped from 300,590 in 2023 to 313,510 in 2024.
Similarly, the higher burden of breast cancer in South American countries is further expected to accelerate segment expansion over the study period. For instance, according to 2023 updated data from the Global Cancer Observatory, around 21,631 new breast cancer cases were diagnosed in Argentina in the year 2022, which is expected to increase over coming years, and the burden of breast cancer was much higher than other cancer types in Argentina. Thus, the fostering demand for breast cancer is expected to fuel segment growth over the study period.
The segment growth is expected to be driven by increased efforts from public and private organizations to foster awareness levels about breast cancer and its management. For instance, in December 2023, Breast Cancer Canada launched a portal, Progress CONNECT, to promote awareness about breast cancer along with recent advances in breast cancer treatment.
In addition, in June 2022, Daiichi Sankyo Brazil undertook a free breast cancer screening for women in Brazil's Amazon region. This initiative further helped to strengthen awareness levels of breast cancer among women. Thus, such initiatives are expected to foster segment growth over the study period.
Moreover, the recent developments by the market players are expected to boost the availability of more breast cancer immunotherapy, which is projected to facilitate segment uptake over the study period. For instance, in April 2024, the United States Food and Drug Administration (U.S.FDA) approved AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for the treatment of metastatic HER2-positive breast cancer in adults.
Similarly, in August 2022, Memorial Sloan Kettering Cancer Center received approval from the United States Food and Drug Administration for its first targeted therapy, Trastuzumab Deruxtecan (T-DXd). The cancer immunotherapy is intended for the management of HER2-low breast cancer patients.
Therefore, the above-mentioned factors, such as the alarming rise in breast cancer, increasing awareness for breast cancer, and several strategic initiatives undertaken by market players, are anticipated to drive the growth of the studied segment.
North America is Expected to Witness Significant Growth Over the Forecast Period
North America is expected to witness significant growth over the forecast period owing to the advanced medical infrastructure, the high burden of cancer, and the strategic initiatives the market players took.
The increase in cancer cases across the region is expected to elevate the demand for cancer immunotherapy, propelling market growth. For instance, according to the data published by the American Cancer Society in 2024, the country reported around 62,770 cases of leukemia in 2024 as compared to 59,610 in 2023. Thus, the alarming increase in the burden of cancer in the region is projected to facilitate market expansion over the study period.
North America is a region with a robust healthcare infrastructure and a supportive research environment. In recent years, the research activities for novel cancer treatment development have increased, and this is projected to accelerate market growth over the study period. For instance, in March 2024, Purdue University, United States, developed advanced nanoparticles to enhance the systemic delivery of cancer immunotherapy.
In addition, in May 2024, the scientists of Washington University School of Medicine received a grant of USD 5 million from the Leukemia & Lymphoma Society (LLS) to develop novel immunotherapies for various blood cancers. Such research activities are expected to accelerate regional market growth over the study period.
Moreover, the recent developments by the market players in the country are expected to boost the market growth in the region. For instance, in March 2023, Hoffmann-La Roche Limited (Roche Canada) received authorization from Health Canada for its cancer therapy, COLUMVI (glofitamab for injection), intended for the management of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Thus, such developments undertaken by industry participants are expected to foster market growth over the study period.
Thus, the above-mentioned factors, such as the increased burden of cancer, growing funding/grants, and several strategic initiatives undertaken by industry participants, are projected to accelerate market growth in the region over the study period.
